The Kingdom of Saudi Arabia is making its boldest move yet in the global longevity race — and this time, it is not just about oil. With Vision 2030 reshaping every sector of the economy, Saudi Arabia has identified human longevity and preventive health as cornerstone industries for the post-oil era. From billion-dollar research foundations to nationwide biomarker screening programs, the Kingdom is rapidly positioning itself as the Middle East’s most ambitious force in longevity medicine.
The Vision 2030 Health Transformation
Saudi Arabia’s Vision 2030 initiative, launched in 2016, set out to diversify the economy away from oil dependence. Health sector transformation has been a central pillar — and in 2026, that transformation is accelerating at an unprecedented pace. The Saudi government has committed over SAR 150 billion (approximately $40 billion USD) to health infrastructure and innovation through 2030, with longevity and preventive medicine receiving a growing share of that investment.
Central to this push is the National Disease Prevention Center, which has launched expansive screening programs targeting cardiovascular disease, diabetes, and metabolic syndrome — the three primary drivers of premature mortality in the Kingdom. These programs are not just clinical screenings; they incorporate epigenetic age testing, comprehensive biomarker panels, and AI-driven health risk modeling that places Saudi Arabia at the forefront of preventive health infrastructure in the region.
Hevolution Foundation: Saudi Arabia’s $2 Billion Longevity Bet
In 2022, Saudi Arabia launched the Hevolution Foundation, a nonprofit with a mandate to fund aging and longevity research globally. With a pledged budget of up to $2 billion annually, Hevolution is one of the largest single funders of longevity science in the world. The foundation focuses on supporting academic research, accelerating clinical trials for geroprotective interventions, and building a translational pipeline that moves discoveries from bench to bedside.
As of 2026, Hevolution has funded over 200 research grants across universities in Saudi Arabia, the United States, and Europe. Its flagship programs include the Geroscience Research Initiative, which supports studies on senolytics, NAD+ precursor therapies, and rapamycin analogs in human trials. The foundation has also established the Hevolution Aging Biology Prize, a $5 million award for breakthrough discoveries in the science of aging — directly competing with similar prizes from the XPRIZE Foundation and the Glenn Foundation for Medical Research.
Why Saudi Arabia Is Investing Billions in Longevity
The Kingdom faces a dual health challenge: a population with one of the world’s highest rates of obesity and diabetes, and a rapidly aging demographic that will strain healthcare systems within the next two decades if left unaddressed. Vision 2030’s health goals explicitly target a 10% reduction in obesity rates and a 15% improvement in life expectancy by 2030. Longevity science, in this context, is not a luxury — it is a strategic national priority.
Beyond the health imperative, Saudi Arabia sees longevity medicine as a growth sector. The Kingdom’s Public Investment Fund (PIF) has backed several longevity-focused ventures, and the Saudi Health Ministry has established regulatory fast-tracks for cutting-edge therapies including stem cell treatments, NAD+ infusion protocols, and personalized vaccine development for age-related diseases.
Saudi Arabia’s Emerging Longevity Clinics and Medical Tourism Push
Riyadh and Jeddah are rapidly building a network of advanced wellness and longevity clinics that cater to high-net-worth individuals both domestically and internationally. Leading institutions such as the Saudi German Hospitals Group and the King Abdullah International Medical Research Center (KAIMRC) have launched longevity and precision medicine divisions offering comprehensive biomarker profiling, AI-assisted health risk assessments, and personalized intervention programs.
The Kingdom is also positioning itself as a destination for longevity tourism, targeting affluent individuals from across the GCC and beyond who seek world-class preventive health services. Recent legislation has eased visa restrictions for medical tourists, and the Saudi Tourism Authority has begun promoting health and wellness travel packages that include multi-day executive health assessments and follow-on concierge health programs.
National Genome Program and Personalized Longevity Medicine
Saudi Arabia’s Saudi Genome Program, launched in 2017 and expanded significantly since 2024, aims to sequence the DNA of 100,000 Saudi citizens to identify genetic risk factors for disease and enable personalized treatment plans. This initiative directly supports longevity medicine by providing the data infrastructure for polygenic risk scoring and pharmacogenomic personalization — two pillars of modern preventive and regenerative medicine.
In 2026, the Kingdom announced integration of genome data with AI-driven health platforms, enabling physicians to generate individualized longevity plans based on genetic predisposition, biomarker status, and lifestyle factors. This convergence of genomics, AI, and precision medicine places Saudi Arabia alongside the United States, the United Kingdom, and Singapore as one of the most advanced nations in data-driven health optimization.
What This Means for the Broader Middle East Longevity Ecosystem
Saudi Arabia’s ambitions are part of a broader Middle East longevity race. The UAE, Qatar, and Bahrain have all launched their own initiatives — from Abu Dhabi’s Health Authority mandate to position the emirate as a global wellness hub, to Qatar’s investment in precision medicine research at Qatar Foundation’s research campuses. However, Saudi Arabia’s scale, resources, and strategic coherence give it a unique position as the regional leader in longevity infrastructure development.
For international longevity providers and medical concierge services, the Kingdom represents a significant market opportunity. The convergence of Vision 2030 investment, a large and health-conscious affluent population, and a regulatory environment increasingly open to cutting-edge medicine makes Saudi Arabia one of the most promising growth markets for longevity services in 2026 and beyond.
Frequently Asked Questions
What is Saudi Arabia’s Vision 2030 health initiative?
Vision 2030 is Saudi Arabia’s strategic plan to diversify the economy and develop public service sectors including health, education, recreation, and tourism. Within health, the initiative targets reductions in obesity and diabetes rates, improvements in life expectancy, and major investments in longevity and preventive medicine infrastructure.
What is the Hevolution Foundation?
The Hevolution Foundation is a Saudi Arabia-based nonprofit committed to funding global aging and longevity research with an annual budget of up to $2 billion. It supports grants, clinical trials, and prizes for discoveries in geroscience and geroprotective interventions.
Can international visitors access Saudi longevity medicine services?
Yes. Saudi Arabia has eased medical tourism visa processes and is developing a premium health tourism sector. Several leading institutions in Riyadh and Jeddah offer executive health and longevity assessment programs for international visitors, with concierge coordination available through specialized providers.
Learn more about premium longevity medicine and personalized health optimization at helixprive.com. Contact Helix Privé for a consultation to explore cutting-edge longevity protocols tailored to your health goals.